Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tci GeneROCO:6879 +0.41%65 Days Payable is 127.64 as of Dec. 2025, which is 13% below its 10-year median of 146.44. GuruFocus rates ROCO:6879 with a GF Score™ of 65/100 and a GF Value™ of NT$48.98 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 701 Biotechnology companies, Tci Gene ranks better than 51.36% on this metric.
Tci Gene's average Accounts Payable for the
six
months ended in Dec. 2025 was NT$38.4 Mil. Tci Gene's Cost of Goods Sold for the
six
months ended in Dec. 2025 was NT$55.0 Mil.
Hence, Tci Gene's Days Payable for the
six
months ended in Dec. 2025 was 127.64.
The historical rank and industry rank for Tci Gene's Days Payable or its related term are showing as below:
ROCO:6879'
s Days Payable Range Over the Past 10 Years
Min: 97.85 Med: 146.44 Max: 190.2
Current: 117.29
During the past 7 years, Tci Gene's highest Days Payable was 190.20. The lowest was 97.85. And the median was 146.44.
ROCO:6879's Days Payable is ranked better than 51.36% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:6879: 117.29
Tci Gene's Days Payable
increased
from Dec. 2024 (125.75) to Dec. 2025 (127.64).
It may suggest that Tci Genedelayed paying its suppliers.
Tci Gene Days Payable Related Terms
Tci Gene Days Payable Historical Data
* Premium members only.
The historical data trend for Tci Gene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Tci Gene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's Days Payable distribution charts can be found below:
* The bar in red indicates where Tci Gene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tci Gene's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tci Gene (ROCO:6879) has a Days Payable of 127.64 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tci Gene and its competitors. This is 13% below median its historical median of 146.44. Over the past decade, Tci Gene's Days Payable has ranged from 97.85 to 190.20. According to the industry distribution chart, Tci Gene ranks #341 out of 701 companies in the Biotechnology industry, placing it in the top 48.6%.
Is Tci Gene's Days Payable too high?
Tci Gene's current Days Payable of 127.64 is 13% below median its 10-year median of 146.44. Over the past 10 years, this metric has ranged from a low of 97.85 to a high of 190.20. The Biotechnology industry median Days Payable is 112.84. Tci Gene's value of 127.64 is 13.1% above this industry median. Based on the distribution chart, Tci Gene ranks #341 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tci Gene has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #341 out of 701 companies for Days Payable. This puts Tci Gene in the upper half of its industry. The industry median Days Payable is 112.84. Tci Gene's value of 127.64 is 13.1% above this benchmark. Historically, Tci Gene's own Days Payable has ranged from 97.85 to 190.20 over the past decade. While the company's 10-year median is 146.44 vs. the industry median of 112.84, Tci Gene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tci Gene's current Days Payable of 127.64 is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tci Gene and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tci Gene's current Days Payable is 127.64, which is 13% below median its own 10-year median of 146.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$48.98, compared to a current price of NT$36.65 — trading 25.2% below its estimated fair value. The current Days Payable is 127.64, which is 13% below median its 10-year median of 146.44 and 13.1% above the Biotechnology industry median of 112.84. Tci Gene's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current Days Payable is 127.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$36.65 is trading 25.2% below its estimated GF Value™ of NT$48.98.
GuruFocus considers Tci Gene to be Modestly Undervalued.
Key valuation signals for ROCO:6879:
Days Payable: 127.64 (13% below median its 10-year median of 146.44)
GF Value™: NT$48.98 vs. price of NT$36.65 (25.2% below fair value)
Industry Position: 13.1% above the Biotechnology median (#341 of 701)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
65GF Score
Get the complete analysis for ROCO:6879
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
